| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 10/29/2013 | US8568374 Intrauterine system |
| 10/29/2013 | US8568363 Frozen compositions and methods for piercing a substrate |
| 10/29/2013 | US8568356 Ambulatory medical apparatus with hand held communication device |
| 10/29/2013 | CA2709545C Topical application and formulation of erythropoietin for skin wound healing |
| 10/29/2013 | CA2680825C Topical formulations having enhanced bioavailability |
| 10/29/2013 | CA2678176C Sustained delivery formulations of rapamycin compounds |
| 10/29/2013 | CA2671975C Film-coated preparation having improved stability |
| 10/29/2013 | CA2622624C Topical film-forming monophasic formulations |
| 10/29/2013 | CA2620829C Method of storing nanoparticle formulations |
| 10/29/2013 | CA2612005C Coated microstructures and method of manufacture thereof |
| 10/29/2013 | CA2609439C Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a pharmaceutical form releasing active substance at reduced ph values |
| 10/29/2013 | CA2605473C Process for preparing quetiapine and quetiapine fumarate |
| 10/29/2013 | CA2593204C Two-piece capsule comprising a preliminary closure for accommodating pharmaceutical preparations for powder inhalers |
| 10/29/2013 | CA2565667C Directly compressible tricalcium phosphate |
| 10/29/2013 | CA2544965C Heat moisture treated starch for the treatment of hypoglycaemia |
| 10/29/2013 | CA2529268C Pharmaceutical formulations of amyloid inhibiting compounds |
| 10/29/2013 | CA2511512C Immunogenic compositions containing phospholipid |
| 10/29/2013 | CA2469134C Novel peptide and pharmaceutical use of the same |
| 10/29/2013 | CA2371794C Human antibiotic proteins |
| 10/24/2013 | WO2013159029A1 Compositions for topical treatment of microbial infections |
| 10/24/2013 | WO2013158961A1 Combination of a non-steroidal anti-inflammatory drug with an anti-histaminic drug intended for ophthalmic use |
| 10/24/2013 | WO2013158871A1 Use of erythropoietin and derivatives for treating hypertension |
| 10/24/2013 | WO2013158814A1 Immediate release, abuse deterrent pharmaceutical compositions |
| 10/24/2013 | WO2013158810A1 Immediate release pharmaceutical compositions with abuse deterrent properties |
| 10/24/2013 | WO2013158719A1 Use of non-metallic cest agents for mri monitoring of nanoparticle delivery |
| 10/24/2013 | WO2013158673A1 Mesoporous silica compositions for modulating immune responses |
| 10/24/2013 | WO2013158661A1 Ocular drug delivery system |
| 10/24/2013 | WO2013158638A1 Stable dosage forms of skeletal muscle relaxants with extended release coating |
| 10/24/2013 | WO2013158620A1 Nanotechnology system for agricultural applications |
| 10/24/2013 | WO2013158618A1 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
| 10/24/2013 | WO2013158549A1 Small magnetite therapeutics and methods of use thereof |
| 10/24/2013 | WO2013158454A2 Compounds and methods for preparation of conjugate reagents |
| 10/24/2013 | WO2013158318A1 Formulations and methods for treatment of acne and inflammatory skin conditions |
| 10/24/2013 | WO2013158317A1 Formulations and methods for treatment of inflammatory skin diseases |
| 10/24/2013 | WO2013158278A1 Compositions and methods comprising energy absorbing materials for follicular delivery |
| 10/24/2013 | WO2013157841A1 Sustained release tablet containing levodropropizine and method for preparing same |
| 10/24/2013 | WO2013157754A1 Method for preparing low dosage entecavir formulation for oral administration |
| 10/24/2013 | WO2013157665A1 Fatty acid derivative-polymer conjugate |
| 10/24/2013 | WO2013157664A1 Tricyclo compound-polymer conjugate |
| 10/24/2013 | WO2013157584A1 Encapsulated formulation |
| 10/24/2013 | WO2013157034A1 Composition for preparing external skin preparation |
| 10/24/2013 | WO2013157010A1 Methods and compositions for rnai-based cancer treatment |
| 10/24/2013 | WO2013157003A1 Growth enhancement of infants |
| 10/24/2013 | WO2013156989A1 Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
| 10/24/2013 | WO2013156944A1 Matrix and device and use thereof for optically-controlled release of chemicals |
| 10/24/2013 | WO2013156853A1 Method of treating acne |
| 10/24/2013 | WO2013156850A1 Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| 10/24/2013 | WO2013156453A1 Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| 10/24/2013 | WO2013156163A1 Taste-masked pharmaceutical compositions containing diclofenac |
| 10/24/2013 | WO2013156088A1 Pellets comprising high active ingredient content |
| 10/24/2013 | WO2013156064A1 Anti-wrinkles cosmetic composition comprising a mu-conopeptide |
| 10/24/2013 | WO2013156035A1 Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| 10/24/2013 | WO2013155742A1 Use of liuweidihuang preparation in preparing drugs for post-operative treatment of cardiac stenting |
| 10/24/2013 | WO2013155741A1 Liuweidihuang liquid pill |
| 10/24/2013 | WO2013155737A1 Pharmaceutical composition for treating aids and preparation method, quality controlling method and use thereof |
| 10/24/2013 | WO2013155719A1 Liver protection health care capsule |
| 10/24/2013 | WO2013155717A1 Body building capsule |
| 10/24/2013 | WO2013155716A1 Capsule to improve sleep |
| 10/24/2013 | WO2013155715A1 Stomach health-preserving capsule |
| 10/24/2013 | WO2013155713A1 Ganoderma lucidum composite capsule |
| 10/24/2013 | WO2013155585A1 Sustained release device for thalidomide and use in eye diseases causing neovascularisation |
| 10/24/2013 | WO2013130785A3 Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same |
| 10/24/2013 | WO2013129889A3 High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient |
| 10/24/2013 | WO2013115736A3 Bilayer tablet formulations of flurbiprofen and glucosamin |
| 10/24/2013 | WO2013111012A3 Methods and compositions for therapeutic agents |
| 10/24/2013 | WO2013100869A3 Lipid-based nanocarrier systems for using cancer treatment |
| 10/24/2013 | WO2013098672A3 Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations |
| 10/24/2013 | WO2013093648A3 Method of producing lipid nanoparticles for drug delivery |
| 10/24/2013 | WO2013088250A4 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| 10/24/2013 | WO2013087734A3 Functionalised silicon nanoparticles |
| 10/24/2013 | WO2013083910A3 Topical emulsions based on mixtures of local eutectic anaesthetics and fatty acids as analgesics, antalgics, or as sexual retardants |
| 10/24/2013 | WO2013076507A3 Platelet lysate gel |
| 10/24/2013 | WO2013072770A3 Pharmaceutical formulations comprising atorvastatin and glimepiride |
| 10/24/2013 | WO2013064911A3 Single use system for sterilely producing lipid-nucleic acid particles |
| 10/24/2013 | WO2012137106A8 The treatment of viral infections |
| 10/24/2013 | US20130281982 Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders |
| 10/24/2013 | US20130281977 Device for controlled release of a bioactive agent |
| 10/24/2013 | US20130281546 Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| 10/24/2013 | US20130281542 Selegiline transdermal system |
| 10/24/2013 | US20130281523 Low dose cannabinoid medicaments |
| 10/24/2013 | US20130281491 Formulations and delivery |
| 10/24/2013 | US20130281480 Oral Drug Delivery System |
| 10/24/2013 | US20130281457 Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid |
| 10/24/2013 | US20130281425 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions |
| 10/24/2013 | US20130281420 Ophthalmic Formulations of Squalamine |
| 10/24/2013 | US20130281417 Implants and methods for treating inflammation-mediated conditions of the eye |
| 10/24/2013 | US20130281416 Pharmaceutical composition |
| 10/24/2013 | US20130281382 Stable lipid-comprising drug delivery complexes and methods for their production |
| 10/24/2013 | US20130280340 Compositions and methods of using lamellar bodies for modifying linear biological macromolecules |
| 10/24/2013 | US20130280339 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same |
| 10/24/2013 | US20130280338 Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| 10/24/2013 | US20130280335 Biomedical implants comprising surface-modified ceramic particles and biodegradable stereo complex polymers, its use for suppressing inflammation and improvement of mechanical property, and preparation method thereof |
| 10/24/2013 | US20130280333 Compositions containing ultra-micronized palmitoyl-ethanolamide |
| 10/24/2013 | US20130280330 Microsphere drug carrier, preparation method, composition and use thereof |
| 10/24/2013 | US20130280329 Methods and compositions for rnai-based cancer treatment |
| 10/24/2013 | US20130280328 Treatment of inflammatory bowel disease with 6-mercaptopurine |
| 10/24/2013 | US20130280327 Zolpidem-based orodispersible pharmaceutical tablet |
| 10/24/2013 | US20130280326 Pharmaceutical composition for oral administration intended to prevent misuse |
| 10/24/2013 | US20130280325 Compressed solid dosage forms |
| 10/24/2013 | US20130280324 Sustained release pharmaceutical compositions comprising pregabalin |